AIM
PDLI

Alambic Investment Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Alambic Investment Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-163,200
Closed -$382K – 438
2018
Q2 		$382K Buy
+163,200
New +$456K 0.1% 241
2016
Q4 		– Sell
-148,800
Closed -$498K – 640
2016
Q3 		$498K Buy
148,800
+8,500
+6% +$27K 0.12% 285
2016
Q2 		$441K Buy
140,300
+48,700
+53% +$162K 0.11% 309
2016
Q1 		$305K Buy
+91,600
New +$286K 0.1% 320

Other funds holding PDLI

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Alambic Investment Management's PDLI Position: Q3 2018 in Review

Alambic Investment Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 163,200 shares — an estimated $382K sold.

Alambic Investment Management first reported a position in PDLI in Q1 2016 and held it in 4 quarters. The position peaked at $498K in Q3 2016. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

  • Alambic Investment Management reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
  • Alambic Investment Management sold 163,200 PDL BioPharma, Inc. shares in Q3 2018, an estimated $382K.
  • Alambic Investment Management first reported a position in PDL BioPharma, Inc. in Q1 2016 and held it in 4 quarters.
  • Alambic Investment Management's PDL BioPharma, Inc. position peaked at $498K in Q3 2016.
  • 152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on Alambic Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.